Status:
TERMINATED
Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a
Lead Sponsor:
Athera Biotechnologies AB
Conditions:
Arterial Inflammation
Cardiovascular Diseases
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis (thickening of the artery wall) and cardiovascular disease. Lipoprotein (...
Eligibility Criteria
Inclusion
- Major inclusion criterion:
- Lp(a) above 50 mg/dL at screening
- Major exclusion criteria:
- Medical history of myocardial infarction (MI) or stroke within 12 months of screening
- Ongoing or paroxysmal atrial fibrillation
- Clinically overt heart failure
- Hypertension defined as ≥180/100 mmHg
- Diabetes mellitus
- Systemic autoimmune diseases requiring treatment
- Cancer, excluding basal cell carcinoma, within the last five years
Exclusion
Key Trial Info
Start Date :
October 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03320265
Start Date
October 11 2017
End Date
July 3 2018
Last Update
July 6 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Vascular Medicine, Academic Medical Center
Amsterdam, Netherlands, 1105 AZ
2
CTC Clinical Trial Consultants AB
Uppsala, Sweden, 75237